½ÃÀ庸°í¼­
»óǰÄÚµå
1591797

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Hemostats & Tissue Sealants Market by Product Type (Hemostats, Tissue sealants), Application (Burn & Trauma Cases, Cardiovascular, General Surgeries), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 105¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 117¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 12.33%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 237¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁöÇ÷Á¦ ¹× Á¶Á÷ ½Ç¶õÆ® ½ÃÀåÀº ¼ö¼ú ½Ã ÃâÇ÷À» ¾ïÁ¦ÇÏ°í »óó ºÀÇÕ ¹× Á¶Á÷ Á¢ÂøÀ» µ½±â À§ÇØ »ç¿ëµÇ´Â ±â±¸ ¹× ¾àǰÀ¸·Î Á¤Àǵ˴ϴÙ. ÀÌ Á¦Ç°µéÀº ¼ö¼ú Áß ÃâÇ÷À» ÃÖ¼ÒÈ­Çϰí ÇÕº´ÁõÀ» ÁÙÀ̸ç ȯÀÚÀÇ È¸º¹ ½Ã°£À» °³¼±Çϱâ À§ÇØ ÀÇ·á ºÐ¾ß¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¦Ç°µéÀº ½ÉÇ÷°ü ¼ö¼ú, ½Å°æ¿Ü°ú, Á¤Çü¿Ü°ú, ÀϹݿܰú µî ´Ù¾çÇÑ ¼ö¼ú ºÐ¾ß¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ´Â º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº °í·ÉÈ­·Î ÀÎÇÑ ¼ö¼ú Áõ°¡, ¼ö¼ú ±â¼úÀÇ ¹ßÀü, Àü ¼¼°è ¿Ü»ó ¹× »ç°í »ç·Ê Áõ°¡ µîÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½À ¼ö¼úÀÇ ±ÞÁõÀ¸·Î È¿°úÀûÀÎ ÁöÇ÷ ¹× ÁöÇ÷Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ½ÃÀå¿¡´Â dzºÎÇÑ ºñÁî´Ï½º ±âȸ°¡ ÀÖÀ¸¸ç, ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±À¸·Î ÀÎÇØ »õ·Î¿î ºñÁî´Ï½º ¼ºÀåÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ÀÌ·¯ÇÑ ½ÃÀåÀ» ¼±Á¡Çϱâ À§ÇØ È¿´ÉÀ» ³ôÀ̰í, ÀÛ¿ë ½Ã°£À» ´ÜÃàÇϰí, ºÎÀÛ¿ëÀ» ÁÙÀÎ Á¦Ç° °³¹ß¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 10.5¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 117¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 237¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 12.33%

±×·¯³ª ½ÃÀå ¼ºÀå¿¡ ¾î·Á¿òÀÌ ¾ø´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ±ÔÁ¦ À庮, ƯÈ÷ FDA ¹× EMA¿Í °°Àº ±â°üÀÇ ¾ö°ÝÇÑ ½ÂÀÎ ÀýÂ÷·Î ÀÎÇØ ½ÅÁ¦Ç° Ãâ½Ã°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °í±Þ ½Ç¶õÆ®¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë°ú ºÀÇÕ»ç ¹× ½ºÅ×ÀÌÇðú °°Àº ±âÁ¸ Á¦Ç°°úÀÇ °æÀïÀº ½ÃÀå ħÅõ¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ±Øº¹Çϱâ À§ÇÑ ÁÖ¿ä Çõ½Å ºÐ¾ß·Î´Â »ýüÀûÇÕ¼º°ú ¸é¿ª¹ÝÀÀ °¨¼Ò¸¦ ¾à¼ÓÇÏ´Â ¹ÙÀÌ¿À ÁöÇ÷Á¦ÀÇ °³¹ßÀÌ ²ÅÈü´Ï´Ù. ¶ÇÇÑ, Á¦Ç°ÀÇ È¿´É°ú Àü´ÞÀ» °³¼±Çϱâ À§ÇÑ ³ª³ë±â¼ú¿¡ ´ëÇÑ Å½±¸´Â °æÀï ¿ìÀ§¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ Æ¯¼º»ó ºó¹øÇÑ Á¦Ç° Ãâ½Ã¿Í Àü·«Àû Á¦ÈÞ·Î ÀÎÇØ ¿ªµ¿ÀûÀÌ°í °æÀïÀûÀÎ ½ÃÀå »óȲÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¿¬±¸°³¹ßÀ» À§ÇÑ ÆÄÆ®³Ê½ÊÀ» Ȱ¿ëÇÏ¿© Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϰí, Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ½ÃÀå ÁøÀÔÀ» °­È­ÇÏ´Â ÇÑÆí, ±ÔÁ¦ Áؼö¸¦ È¿À²ÀûÀ¸·Î ÃæÁ·Çϱâ À§ÇØ ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè¿¡ ÁýÁßÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀÇ À¯Çà°ú Àû½Ã ¼ö¼úÀÇ Çʿ伺
    • »ýü °íºÐÀÚ ±â¹Ý ÀÏȸ¿ë ÁöÇ÷Á¦ÀÇ µîÀå
    • ½Å·ÚÇÒ ¼ö ÀÖ´Â ¿Â¶óÀÎ ÀÇ·á±â±â ä³ÎÀ» ÅëÇÑ ÁöÇ÷Á¦ÀÇ °¡¿ë¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿Ü°ú¿ë ½Ç¶õÆ®ÀÇ ³·Àº ¿ÜÇü ǰÁú°ú ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Â÷¼¼´ë Á¶Á÷ ½Ç¶õÆ® ¹× ÁöÇ÷Á¦ ¼Ò°³
    • »óó Ä¡À¯ ¹× ºÀÇÕ °ü¸®¿¡ ÁßÁ¡À» µÐ ³ë·Â
  • ½ÃÀå °úÁ¦
    • ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® »ç¿ë¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±âÁØ

Portre's Five Forces: ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÏ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå : Á¦Ç° À¯Çüº°

  • ÁöÇ÷Á¦
    • ¾×Ƽºê ÁöÇ÷Á¦
    • À¯µ¿¼º ÁöÇ÷Àç
    • ±â°è½Ä ÁöÇ÷ °âÀÚ
  • Á¶Á÷ ½Ç¶õÆ®
    • ÇǺ기 ½Ç¶õÆ®
    • ÇÕ¼º ½Ç¶õÆ®

Á¦7Àå ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå : ¿ëµµº°

  • È­»ó ¹× ¿Ü»ó Áõ·Ê
  • ½ÉÀåÇ÷°ü
  • ÀϹݿܰú
  • ½Å°æÇÐÀû
  • Á¤Çü¿Ü°ú
  • Àç°Ç ¼ö¼ú
  • ºñ´¢±â°ú

Á¦8Àå ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦112Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁöÇ÷Á¦ ¹× Á¶Á÷¿ë ½Ç¶õÆ® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Advanced Medical Solutions Group PLC
  • Aegis Lifesciences Private Limited.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • CooperSurgical, Inc.
  • CryoLife, Inc.
  • CSL Behring
  • CuraMedical B.V.
  • Grifols, S.A.
  • Hemostasis, LLC
  • Hologic, Inc.
  • Integra LifeSciences Corporation
  • Johnson & Johnson Services, Inc.
  • KAKEN PHARMACEUTICAL CO., LTD.
  • KATSAN Katgut Sanayi ve Tic. A.S.
  • Medline Industries, LP.
  • Medtronic PLC
  • Olympus Corporation
  • Owens & Minor
  • Pfizer, Inc.
  • Smith & Nephew PLC
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
  • Vivostat A/S
  • Zimmer Biomet
LSH

The Hemostats & Tissue Sealants Market was valued at USD 10.50 billion in 2023, expected to reach USD 11.78 billion in 2024, and is projected to grow at a CAGR of 12.33%, to USD 23.72 billion by 2030.

The market for hemostats and tissue sealants is defined by devices and agents used to control bleeding and assist in wound closure or tissue adhesion during surgical procedures. These products are necessary in healthcare to minimize intraoperative blood loss, thereby reducing complications and improving patient recovery times. They find applications across various surgical disciplines, including cardiovascular, neurological, orthopedic, and general surgery. Key end-users include hospitals, clinics, and ambulatory surgical centers. Growth in this market is influenced by increasing surgical procedures due to an aging population, advancements in surgical techniques, and a rise in trauma and accident cases globally. The surge in minimally invasive procedures has created significant demand for effective hemostatic and sealing agents. Opportunities abound with emerging markets in Asia-Pacific and Latin America, where healthcare infrastructure improvements open new avenues for business growth. Companies should focus on developing products with enhanced efficacy, quicker action times, and reduced side effects to capture these markets.

KEY MARKET STATISTICS
Base Year [2023] USD 10.50 billion
Estimated Year [2024] USD 11.78 billion
Forecast Year [2030] USD 23.72 billion
CAGR (%) 12.33%

However, market growth is not without challenges. Regulatory hurdles, particularly stringent approval processes from bodies like the FDA and EMA, can delay the introduction of new products. Additionally, high costs associated with advanced sealants and competition from traditional products like sutures and staples can hinder market penetration. To overcome these, key areas of innovation include the development of bio-based hemostats, which promise biocompatibility and reduced immune responses. Moreover, exploration into nanotechnology for improved product efficacy and delivery can provide competitive advantages. As for the market's nature, it is dynamic and competitive, with frequent product launches and strategic collaborations shaping its landscape. Companies are advised to leverage partnerships for R&D to boost product portfolios and engage in strategic alliances to enhance market reach while focusing on rigorous clinical trials to meet regulatory compliance efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemostats & Tissue Sealants Market

The Hemostats & Tissue Sealants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic disorders and need for timely surgeries
    • Rise of biopolymer-based disposable hemostats
    • Availability of hemostats through trusted online medical device channels
  • Market Restraints
    • Low outlining quality and high costs of surgical sealants
  • Market Opportunities
    • Introduction of new-generation tissue sealants and hemostatic agents
    • Initiatives focusing on wound healing and closure management
  • Market Challenges
    • Strict standards regarding the utilization of hemostats & tissue sealants

Porter's Five Forces: A Strategic Tool for Navigating the Hemostats & Tissue Sealants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemostats & Tissue Sealants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemostats & Tissue Sealants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemostats & Tissue Sealants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemostats & Tissue Sealants Market

A detailed market share analysis in the Hemostats & Tissue Sealants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemostats & Tissue Sealants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemostats & Tissue Sealants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemostats & Tissue Sealants Market

A strategic analysis of the Hemostats & Tissue Sealants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemostats & Tissue Sealants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Advanced Medical Solutions Group PLC, Aegis Lifesciences Private Limited., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., CooperSurgical, Inc., CryoLife, Inc., CSL Behring, CuraMedical B.V., Grifols, S.A., Hemostasis, LLC, Hologic, Inc., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., KAKEN PHARMACEUTICAL CO., LTD., KATSAN Katgut Sanayi ve Tic. A.S., Medline Industries, LP., Medtronic PLC, Olympus Corporation, Owens & Minor, Pfizer, Inc., Smith & Nephew PLC, Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Thermo Fisher Scientific Inc., Vivostat A/S, and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Hemostats & Tissue Sealants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Hemostats and Tissue sealants. The Hemostats is further studied across Active Hemostats, Flowable Hemostats, and Mechanical Hemostats. The Tissue sealants is further studied across Fibrin Sealants and Synthetic Sealants.
  • Based on Application, market is studied across Burn & Trauma Cases, Cardiovascular, General Surgeries, Neurological, Orthopedic, Reconstructive Surgeries, and Urological.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic disorders and need for timely surgeries
      • 5.1.1.2. Rise of biopolymer-based disposable hemostats
      • 5.1.1.3. Availability of hemostats through trusted online medical device channels
    • 5.1.2. Restraints
      • 5.1.2.1. Low outlining quality and high costs of surgical sealants
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new-generation tissue sealants and hemostatic agents
      • 5.1.3.2. Initiatives focusing on wound healing and closure management
    • 5.1.4. Challenges
      • 5.1.4.1. Strict standards regarding the utilization of hemostats & tissue sealants
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemostats & Tissue Sealants Market, by Product Type

  • 6.1. Introduction
  • 6.2. Hemostats
    • 6.2.1. Active Hemostats
    • 6.2.2. Flowable Hemostats
    • 6.2.3. Mechanical Hemostats
  • 6.3. Tissue sealants
    • 6.3.1. Fibrin Sealants
    • 6.3.2. Synthetic Sealants

7. Hemostats & Tissue Sealants Market, by Application

  • 7.1. Introduction
  • 7.2. Burn & Trauma Cases
  • 7.3. Cardiovascular
  • 7.4. General Surgeries
  • 7.5. Neurological
  • 7.6. Orthopedic
  • 7.7. Reconstructive Surgeries
  • 7.8. Urological

8. Hemostats & Tissue Sealants Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Hemostats & Tissue Sealants Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemostats & Tissue Sealants Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemostats & Tissue Sealants Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Olympus Launches EndoClot Hemostatic Agents and Submucosal Injection Agent in European Markets
    • 12.3.2. Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
    • 12.3.3. Advamedica Inc Announces FDA Clearance for Ax-Surgi Surgical Hemostat
    • 12.3.4. Team Develops Extracellular Matrix-Based Sticky Sealants For Corneal Tissue Reconstruction
    • 12.3.5. Medcura Receives Breakthrough Device Designation for its LifeGel(TM) Absorbable Surgical Hemostat
    • 12.3.6. Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market
    • 12.3.7. ZEISS Receives FDA Clearance for MTLawton - A New Generation of Bipolar Forceps for Electrosurgery
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Advanced Medical Solutions Group PLC
  • 3. Aegis Lifesciences Private Limited.
  • 4. B. Braun SE
  • 5. Baxter International Inc.
  • 6. Becton, Dickinson and Company
  • 7. Cardinal Health, Inc.
  • 8. CooperSurgical, Inc.
  • 9. CryoLife, Inc.
  • 10. CSL Behring
  • 11. CuraMedical B.V.
  • 12. Grifols, S.A.
  • 13. Hemostasis, LLC
  • 14. Hologic, Inc.
  • 15. Integra LifeSciences Corporation
  • 16. Johnson & Johnson Services, Inc.
  • 17. KAKEN PHARMACEUTICAL CO., LTD.
  • 18. KATSAN Katgut Sanayi ve Tic. A.S.
  • 19. Medline Industries, LP.
  • 20. Medtronic PLC
  • 21. Olympus Corporation
  • 22. Owens & Minor
  • 23. Pfizer, Inc.
  • 24. Smith & Nephew PLC
  • 25. Stryker Corporation
  • 26. Teleflex Incorporated
  • 27. Terumo Corporation
  • 28. Thermo Fisher Scientific Inc.
  • 29. Vivostat A/S
  • 30. Zimmer Biomet
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦